Eli Lilly and Company (LLY) Stock Forecast & Price Target

$839.44 -3.13 (-0.37%)

Closing price 03/21/2025 03:59 PM Eastern

Extended Trading

$841.00 +1.56 (+0.19%)

As of 03/21/2025 07:59 PM Eastern

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
3

Buy
17

Based on 20 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 3 have given a hold rating, and 17 have given a buy rating for LLY.

Consensus Price Target

$1,009.72
20.28% Upside

According to the 20 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,009.72. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $723.00. The average price target represents a forecasted upside of 20.28% from the current price of $839.44.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

LLY Analyst Ratings Over Time

Type	Current Forecast 3/23/24 to 3/23/25	1 Month Ago 2/22/24 to 2/21/25	3 Months Ago 12/24/23 to 12/23/24	1 Year Ago 3/24/23 to 3/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,009.72	$990.79	$1,002.22	$689.52
Forecasted Upside	20.28% Upside	13.35% Upside	25.86% Upside	-10.52% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	20.28% Upside	21,753.34% Upside	18.90% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/6/2025	Morgan Stanley 3 of 5 stars		Set Target		$1,146.00	+36.69%
3/5/2025	Wells Fargo & Company 3 of 5 stars	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$970.00 ➝ $1,100.00	+19.87%
2/3/2025	Truist Financial 2 of 5 stars	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$1,029.00 ➝ $1,038.00	+27.51%
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$1,250.00 ➝ $1,190.00	+47.25%
1/17/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$950.00	+8.68%
1/16/2025	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$970.00	+10.97%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$997.00	+24.17%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,000.00	+27.23%
11/4/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Baker Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
11/4/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,025.00 ➝ $1,015.00	+25.66%
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,025.00 ➝ $975.00	+16.30%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$1,100.00	+20.04%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$885.00 ➝ $885.00	-4.27%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,050.00 ➝ $1,100.00	+17.67%
9/5/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/16/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$884.00 ➝ $1,030.00	+10.89%
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$1,001.00 ➝ $1,101.00	+30.36%
6/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$994.00 ➝ $1,015.00	+12.98%
5/14/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$770.00 ➝ $840.00	+11.04%
4/11/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$650.00 ➝ $723.00	-5.02%
4/3/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/21/2024	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$820.00	+8.50%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$612.00 ➝ $710.00	+20.28%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
8/8/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$560.00	+28.82%
6/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/1/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$410.00 ➝ $458.00	+15.70%
4/28/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:22 PM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 18, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

The company recently reported a strong net margin of 23.51%, indicating efficient management and profitability, which can lead to higher returns for investors.
Eli Lilly and Co has a robust return on equity of 85.24%, suggesting that the company is effective at generating profits from its equity, making it an attractive investment.
With a current stock price around $818.24, the company is engaging in a significant share repurchase plan of $15 billion, which often signals that the board believes the stock is undervalued, potentially leading to price appreciation.
Analysts have a consensus rating of "Moderate Buy" with a target price of $1,009.72, indicating positive sentiment and potential for growth in the stock price.
The company has seen increased institutional interest, with 82.53% of its stock owned by institutional investors and hedge funds, which often reflects confidence in the company's future performance.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

The recent earnings report showed that the company missed analysts' consensus estimates by $0.13, which could raise concerns about its ability to meet future expectations.
Insider selling activity, such as the recent sale of 1,000 shares by the Chief Accounting Officer, may indicate a lack of confidence among insiders regarding the stock's short-term performance.
Despite a strong consensus rating, three analysts have rated the stock as a hold, suggesting that some market participants may be cautious about its current valuation.
Recent price target adjustments by analysts, including a reduction from Citigroup, may indicate a more cautious outlook on the stock's near-term performance.
The competitive landscape in the pharmaceutical industry is intense, and any setbacks in product development or regulatory approvals could negatively impact the company's growth prospects.

LLY Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,009.72, with a high forecast of $1,190.00 and a low forecast of $723.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
: According to analysts, Eli Lilly and Company's stock has a predicted upside of 20.28% based on their 12-month stock forecasts.
: Eli Lilly and Company has been rated by research analysts at Berenberg Bank, Citigroup, Leerink Partners, Morgan Stanley, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.85 while the average consensus rating score for "medical" companies is 2.82. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:LLY) was last updated on 3/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target